Business faces "fundamental change" in protecting inventions in the USA

15 March 2013

From Saturday, March 16, organizations looking to protect their inventions in the USA will face significantly different requirements in the ways they apply to protect their products and services under US patent law. In particular, the US first-to-invent system will be replaced by the more widespread first-to-file system, comments a UK-based intellectual property specialist at law firm Marks & Clerk.

Under current US patent law, parties that can prove they invented a product or process first are granted patent protection over parties that cannot, regardless of which party first filed for protection with the US Patent and Trademark Office (USPTO). The America Invents Act (AIA) will be replace this system with a first-to-file arrangement, meaning that, whichever party first files for protection (if all is in order) will obtain the patent, regardless of who first invented the product or process.

Post Grant Reviews to be available

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology